| Abstract |
Objective: To investigate the clinical effect of aspirin combined with simvastatin in the prevention and treatment of ischemic cerebrovascular disease. Methods: The patients with coronary heart disease and heart failure admitted to our hospital were the main analysis objects of this study. The study was carried out in June 2020 and ended in June 2021. During this period, 80 patients with ischemic cerebrovascular disease were selected. And set up two groups, the reference group and the study group, and randomly group the patients according to the method of computer. The 40 cases in each group are divided into two groups. At the same time, in order to highlight the effect of the prevention and treatment methods in this study, different applications are applied to patients in different groups. In order to complete the controlled study, the treatment method of the former is aspirin, and the treatment method of the latter is the combination therapy, namely aspirin + simvastatin. After the above treatment methods are implemented, relevant data needs to be recorded in detail, especially the clinical effects of patients after treatment and the follow-up results after 1 year. Detailed statistics should be made and the actual situation of the two groups should be compared. Results: The statistical results of the two groups of patients after treatment showed that {reference group 67.5% (28/40) compared to the study group 85.0% (34/40)}, the latter has a significant advantage (P<0.05), the difference is And statistically significant. The patients were followed up for 1 year after treatment. In the study group, there were 2 cases, 2 cases, 1 case, and 1 case of myocardial infarction, transient cerebral ischemia, cerebral infarction, and death, respectively, and the reference group had 4 cases, respectively. In 5 cases, 3 cases, and 2 cases, after data recording, the latter had a higher number of cases, and the difference was statistically significant (P<0.05). Conclusion: The use of aspirin combined with simvastatin for the treatment of ischemic cerebrovascular disease can not only improve the clinical effect of patients, but also promote the improvement of safety, which can broaden the promotion and application value after treatment in the future.
|